Dr. Eric Topol on finding the way back from the “abject failure” of EHR...

Dr. Eric Topol speaks at the Nvidia’s GTC Conference in San Jose. The seemingly contradictory idea that technology can make healthcare more humane is the central thesis...

What’s behind sky-high valuations of biopharma startups?

2018 was undoubtedly one of the most important years ever for biopharma, setting records for valuations and dealmaking. But a paper published in January called some...

What’s the current state of population health?

The fourth annual study from healthcare consulting firm Numerof & Associates found progress toward implementing population health models seems to have stalled in 2018. The report, which was...

FDA approves Roche’s Tecentriq for first-line, extensive-stage small-cell lung cancer

Slightly more than a week after approving it as the first-ever immunotherapy treatment for breast cancer, the Food and Drug Administration has approved Roche’s Tecentriq (atezolizumab)...

4 ways a branded app can dramatically cut ED wait times, improve patient experience

Drive around any medium or large U.S. city, and you’re likely to see a local health system advertising its emergency department (ED) wait times like convenience...

HR and benefits software startup Ease nabs $19 million Series B

San Francisco, California-based Ease has raised a $19 million Series B led by Centana Growth Partners as it looks to continue its growth trajectory, enter new...

Check out the speaker lineup for MedCity INVEST

MedCity INVEST is coming up next month. We’ve lined up a fantastic group of speakers for the two day conference in Chicago at the Ritz Carlton...

Anthem inks novel partnership to link Indiana Medicaid patients to free legal services

For many Medicaid members, circumstances like eviction, past criminal convictions and a suspended driver’s license can stand in the way of better health and a pathway...

Intermountain Healthcare expands its home-based services through Intermountain at Home program

Intermountain Healthcare in Salt Lake City has revealed that it is growing its home-based service offerings this year to include primary care, some traditional hospital-level services...

Cold Genesys secures $22M Series C round for oncolytic virus in bladder cancer

The company’s lead product candidate, CG0070, has completed a Phase II study and will be tested in another trial, combined with Merck’s Keytruda. Source link

Must Read